Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats

Journal of Neuroimmunology

Volumn 71, Issue 1-2, 1996, Pages 131-137

  Inoue, Atsushi ^a   Koh, Chang Sung ^a   Shimada, Kazuhide ^a   Yanagisawa, Nobuo ^a   Yoshimura, Kazuhiko ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

batroxobin; blood brain barrier; cell transferred experimental allergic encephalomyelitis; fibrin deposits

Indexed keywords

BATROXOBIN; FIBRIN; FIBRINOGEN;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CELL INFILTRATION; CONTROLLED STUDY; FIBRIN DEPOSITION; FIBRINOLYSIS; HISTOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BATROXOBIN; BLOOD-BRAIN BARRIER; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; MALE; RATS; RATS, INBRED LEW;

EID: 0030561019     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(96)00150-6     Document Type: Article

References (38)

1. Adams, C.W.M., Poston, R.N., Buk, S.J., Sidhu, Y.S. and Vipond, H. (1985) Inflammatory vasculitis in multiple sclerosis.
2. Bernik M.B., Oller E.P. Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. J. Clin. Invest. 52:1973;823-834.
3. Brown A.M., McFarlin D.E. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab. Invest. 45:1981;278-284.
4. Brown A.M., McFarlin D.E., Raine C.S. Chronic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab. Invest. 46:1982;171-185.
5. Edgington, T.S., Heilin, H., Gregory, S.A., Levy, G., Fair, D.S. and Schwartz, B.S. (1985) Cellular pathways and signals for the induction of biosynthesis by the cells of the monocyte lineage of initiators of the coagulation protease cascade. In: ed. R. Van Furth, Mononuclear Phagocytes. Martinus Nijhoff, Boston, MA, pp. 687-696.
6. Egberg, N. (1973) Coagulation studies in patients treated with Defibrase. Acta Med. Scand. 1-12.
7. Fletcher A.P., Alkjaersig N., Sherry S. Fibrinolytic mechanisms and the development of thrombolytic therapy. Am. J. Med. 33:1962;738-752.
8. Fritz R.B., Chou C.-H.J., McFarlin D.E. Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J×PL/J) F1 mice by myelin basic protein and its peptides: localization of a second encephalitogenic determinant. J. Immunol. 130:1983;191-194.
9. Geczy C.L., Roberts I.M., Meyer P., Bernard C.C.A. Susceptibility and resistance to experimental autoimmune encephalomyelitis and neuritis in the guinea pig correlate with the induction of procoagulant and anticoagulant activities. J. Immunol. 133:1984;3026-3036.
10. Gerdin B., Saldeen T. Effect of fibrin degradation products on microvascular permeability. Thromb. Res. 13:1978;995-1006.
11. Johns T.G., Rosbo N.K., Menon K.K., Abo S., Gonzales M.F., Bernard C.C.A. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J. Immunol. 154:1995;5536-5541.
12. Juhler M., Barry D.I., Offner H., Konat G., Klinken L., Paulson O.B. Blood-brain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat. Brain Res. 302:1984;347-355.
13. Koh C.-S., Paterson P.Y. Suppression of clinical signs of cell transferred experimental allergic encephalomyelitis and altered cerebrovascular permeability in Lewis rats treated with a plasminogen activator inhibitor. Cell. Immunol. 107:1987;52-63.
14. Koh C.-S., Kwaan H.C., Paterson P.Y. Neurovascular fibrinolytic activity in normal Lewis rats and rats with cell-transferred experimental allergic encephalomyelitis. J. Neuroimmunol. 28:1990;189-200.
15. Koh C.-S., Gausas J., Paterson P.Y. Concordance and localization of maximal vascular permeability change and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis. J. Neuroimmunol. 38:1992;85-94.
16. Koh C.-S., Gausas J., Paterson P.Y. Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J. Neuroimmunol. 47:1993;141-146.
17. Kwaan H.C., Lo R., McFadzean A.J.S. On the production of plasma fibrinolytic activity within veins. Clin. Sci. 16:1957;241-253.
18. Lane D.A. Fibrinogen derivatives in plasma. Br. J. Haematol. 47:1981;329-335.
19. Levine S., Sowinski R. Localization of toxic encephalopathies near lesions of experimental allergic encephalomyelitis. Am. J. Pathol. 107:1982;135-141.
20. McDonagh J., McDonagh R.P. Alternative pathways for the activation of factor XIII. Brit. J. Haematol. 30:1975;465-479.
21. McRae B.L., Kennedy M.K., Tan L.J., Dal Canto M.C., Miller S.D. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38:1992;229-240.
22. Miller S.D., Karpus W.J. The immunopathogenesis and regulation of T-cell-mediated demyelinating disease. Immunol. Today. 15:1994;356-361.
23. Niewiarowski S., Regoeczi E., Stewart G., Senyi A.F., Mustard J.F. Platelet interaction with polymerizing fibrin. J. Clin. Invest. 51:1972;685-700.
24. Ohba M., Aoyama M. Defibrinogenating effects of Batroxobin (DF-521) on plasma fibrinogen concentration of experimental animals - A comparative study on seven different species. Med. Pharmaco. 14:1985;1061-1071. Japanese.
25. Oldstone M.D., Dixon F.J. Immunohistochemical study of allergic encephalomyelitis. Am. J. Pathol. 52:1968;251-263.
26. Paterson P.Y. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J. Exp. Med. 111:1960;119-136.
27. Paterson P.Y. Experimental allergic encephalomyelitis: Role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed. Proc. 35:1976;2428-2434.
28. Paterson P.Y. Molecular and cellular determinants of neuroimmunologic inflammatory disease. Fed. Proc. 41:1982;2569-2576.
29. Paterson P.Y., Gausas J., Koh C.-S., Kwaan H.C. The clotting system: gatekeeper of cerebrovascular permeability and monitor of clinical manifestations of neuroautoimmune disease. Trans. Am. Clin. Climatol. Assoc. 97:1985;149-157.
30. - T lymphocytes. J. Immunol. 127:1981;1420-1423.
31. Paterson P.Y., Koh C.-S., Kwaan H.C. Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed. Proc. 46:1987;91-96.
32. Paterson, P.Y. and Swanborg, R.H. (1988) In: ed. M. Sampter, D.W. Talmage, M.M. Frank, K.F. Austen and H.N. Claman, Immunological Diseases. Little, Brown and Co., pp. 1877-1916.
33. Rosbo N.K., Mendel I., Ben-Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: Preliminary analysis of MOG T cell epitopes. Eur. J. Immunol. 25:1995;985-993.
34. Sueishi K., Nanno S., Tanaka K. Permeability enhancing and chemotactic activities of lower molecular weight degradation products of human fibrinogen. Thromb. Haemostasis. 45:1981;90-94.
35. Swanborg R.H., Swiekosz J.E., Saieg R.G. Studies on the species-variability of experimental allergic encephalomyelitis in guinea pigs and rats. J. Immunol. 112:1974;594-600.
36. Trotter J.L., Clark H.B., Collins K.G., Wegeschiede C.L., Scarpellini J.D. Myelin proteolipid protein induces demyelinating disease in mice. J. Neurol. Sci. 79:1987;173-188.
37. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1989;1523-1527.
38. Waibl H. Contribution to the topography of the spinal cord of the albino rat (Rattus norvegicus). Adv. Anat. Embryol. Cell Biol. 47:1973;1-42.